416 related articles for article (PubMed ID: 29455667)
21. Signaling network of the Btk family kinases.
Qiu Y; Kung HJ
Oncogene; 2000 Nov; 19(49):5651-61. PubMed ID: 11114746
[TBL] [Abstract][Full Text] [Related]
22. Platelet activation: new aspects.
Fox JE
Haemostasis; 1996 Oct; 26 Suppl 4():102-31. PubMed ID: 8979117
[TBL] [Abstract][Full Text] [Related]
23. Roles of non-receptor tyrosine kinases in pathogenesis and treatment of depression.
Wang JQ; Derges JD; Bodepudi A; Pokala N; Mao LM
J Integr Neurosci; 2022 Jan; 21(1):25. PubMed ID: 35164461
[TBL] [Abstract][Full Text] [Related]
24. SH2 and PTB domains in tyrosine kinase signaling.
Schlessinger J; Lemmon MA
Sci STKE; 2003 Jul; 2003(191):RE12. PubMed ID: 12865499
[TBL] [Abstract][Full Text] [Related]
25. Targeting Wnt signaling pseudokinases in hematological cancers.
Karvonen H; Perttilä R; Niininen W; Barker H; Ungureanu D
Eur J Haematol; 2018 Oct; 101(4):457-465. PubMed ID: 29989208
[TBL] [Abstract][Full Text] [Related]
26. Src homology 2 domain substitution modulates the kinase and transforming activities of the Fes protein-tyrosine kinase.
Rogers JA; Cheng HY; Smithgall TE
Cell Growth Differ; 2000 Nov; 11(11):581-92. PubMed ID: 11095247
[TBL] [Abstract][Full Text] [Related]
27. Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its src homology 2 domain and major autophosphorylation site (Tyr-713).
Hjermstad SJ; Peters KL; Briggs SD; Glazer RI; Smithgall TE
Oncogene; 1993 Aug; 8(8):2283-92. PubMed ID: 7687763
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine kinase signalling pathways.
Pawson T
Princess Takamatsu Symp; 1994; 24():303-22. PubMed ID: 8983084
[TBL] [Abstract][Full Text] [Related]
29. Structure-function relationships in Src family and related protein tyrosine kinases.
Superti-Furga G; Courtneidge SA
Bioessays; 1995 Apr; 17(4):321-30. PubMed ID: 7537961
[TBL] [Abstract][Full Text] [Related]
30. A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling.
García-Martínez JM; Calcabrini A; González L; Martín-Forero E; Agulló-Ortuño MT; Simon V; Watkin H; Anderson SM; Roche S; Martín-Pérez J
Cell Signal; 2010 Mar; 22(3):415-26. PubMed ID: 19892015
[TBL] [Abstract][Full Text] [Related]
31. [The signal transduction of receptor tyrosine kinase].
Takada T; Matozaki T; Kasuga M
Nihon Rinsho; 1998 Jul; 56(7):1756-62. PubMed ID: 9702050
[TBL] [Abstract][Full Text] [Related]
32. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Chalandon Y; Schwaller J
Haematologica; 2005 Jul; 90(7):949-68. PubMed ID: 15996933
[TBL] [Abstract][Full Text] [Related]
33. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
34. Natural products against hematological malignancies and identification of their targets.
Xu Y; Liu J; Wu Y; Guo Q; Sun H; Chen G
Sci China Life Sci; 2015 Dec; 58(12):1191-201. PubMed ID: 26566803
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.
Nefedova Y; Gabrilovich D
Drug Resist Updat; 2008 Dec; 11(6):210-8. PubMed ID: 18951834
[TBL] [Abstract][Full Text] [Related]
36. SH2 domain-mediated interaction of inhibitory protein tyrosine kinase Csk with protein tyrosine phosphatase-HSCF.
Wang B; Lemay S; Tsai S; Veillette A
Mol Cell Biol; 2001 Feb; 21(4):1077-88. PubMed ID: 11158295
[TBL] [Abstract][Full Text] [Related]
37. [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
Klener P; Klener P
Klin Onkol; 2010; 23(4):203-9. PubMed ID: 20806817
[TBL] [Abstract][Full Text] [Related]
38. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement.
Moarefi I; LaFevre-Bernt M; Sicheri F; Huse M; Lee CH; Kuriyan J; Miller WT
Nature; 1997 Feb; 385(6617):650-3. PubMed ID: 9024665
[TBL] [Abstract][Full Text] [Related]
39. Structure of the regulatory domains of the Src-family tyrosine kinase Lck.
Eck MJ; Atwell SK; Shoelson SE; Harrison SC
Nature; 1994 Apr; 368(6473):764-9. PubMed ID: 7512222
[TBL] [Abstract][Full Text] [Related]
40. [Kinase inhibitors against hematological malignancies].
Tojo A
Nihon Rinsho; 2014 Jun; 72(6):1118-24. PubMed ID: 25016814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
